In an in vivo study, wild-type MSCs and EGR1-deficient MSCs were separately prepared from wild-type (Egr1+/+) and Egr1-null (Egr1−/−) mice, and then co-injected subcutaneously with 4T1 mouse breast cancer cells. Here, EGR1 is linked to breast carcinoma.